Related Experiment Video
Updated: Aug 20, 2026

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
Decreased expression of Apaf-1 with progression of melanoma
Rita Mustika1, Arief Budiyanto, Chikako Nishigori
1Division of Dermatology, Clinical Molecular Medicine, Faculty of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Abstract:
Defects in apoptotic system may contribute in the pathogenesis and resistance of malignant melanoma cells to chemotherapy. Apoptotic protease-activating factor-1 (Apaf-1) is a cell death effector that acts with cytochrome c and caspase-9 to mediate apoptosis. Recently it was shown that metastatic melanomas often lose Apaf-1 and are concomitantly resistant to apoptosis. It is not known, however, whether Apaf-1 protein is lost during melanoma progression from localized to metastatic tumor. To this end, we evaluated Apaf-1 protein expression by immunohistochemistry in 10 cases of human nevi, 11 melanomas in situ, 26 primary melanomas and 15 metastases. Significant decreases in Apaf-1 expression was observed when comparing nevi and melanomas (chi-square = 33.719; P < 0.0001). Moreover, primary melanomas with greater tumor thickness showed lesser expression of Apaf-1 (chi-square = 16.182; P < 0.003). Intriguingly, we were unable to detect Apaf-1 expression in lesions of metastatic melanomas. These data demonstrated that there is an inverse correlation between Apaf-1 expression and pathologic stage of melanoma. This suggests that the decreased expression of Apaf-1 seen in correlation with melanoma progression renders melanoma more resistant to chemotherapy.
Insights
Melanoma cells lose Apoptotic protease-activating factor-1 (Apaf-1) protein as tumors progress, leading to chemotherapy resistance. Reduced Apaf-1 expression correlates with advanced melanoma stages, including metastases.
Area of Science:
- Oncology
- Cell Biology
- Molecular Pathology
Background:
- Defects in the apoptotic system are implicated in melanoma pathogenesis and chemotherapy resistance.
- Apoptotic protease-activating factor-1 (Apaf-1) is crucial for apoptosis, working with cytochrome c and caspase-9.
- Metastatic melanomas frequently exhibit Apaf-1 loss and apoptosis resistance.
Purpose of the Study:
- To investigate whether Apaf-1 protein is lost during melanoma progression from localized to metastatic stages.
- To determine the correlation between Apaf-1 expression levels and melanoma pathological stage.
Main Methods:
- Immunohistochemistry was used to evaluate Apaf-1 protein expression.
- Apaf-1 expression was assessed in various melanoma lesions: nevi, melanomas in situ, primary melanomas, and metastases.
Main Results:
- A significant decrease in Apaf-1 expression was observed when comparing nevi and melanomas (P < 0.0001).
- Primary melanomas with greater tumor thickness showed reduced Apaf-1 expression (P < 0.003).
- Apaf-1 expression was undetectable in metastatic melanoma lesions.
Conclusions:
- There is an inverse correlation between Apaf-1 expression and the pathological stage of melanoma.
- Decreased Apaf-1 expression during melanoma progression likely contributes to increased chemotherapy resistance.
Related Concept Videos
The Intrinsic Apoptotic Pathway
Abnormal Proliferation
The Extrinsic Apoptotic Pathway
MAPK Signaling Cascades
